share_log

Needham Reiterates Buy on Mereo BioPharma Group, Maintains $7 Price Target

Benzinga ·  Mar 26 15:35

Needham analyst Gil Blum reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $7 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 294

Recommended

Write a comment